Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients
暂无分享,去创建一个
E. Ziv | N. Camp | C. Vachon | G. Giles | J. Spinelli | M. Hildebrandt | S. Berndt | R. Milne | S. Slager | D. Campa | F. Canzian | R. Reis | F. Gemignani | C. Dumontet | M. Kruszewski | A. Vangsted | H. Marques | E. Brown | N. Abildgaard | R. Waller | W. Tomczak | T. Barington | A. Norman | R. García-Sanz | D. Zawirska | N. F. Andersen | A. Butrym | J. Martínez-López | G. Mazur | J. Hofmann | W. Prejzner | G. Buda | A. Jurczyszyn | M. Markiewicz | J. Sainz | K. Jamroziak | J. Várkonyi | A. Suska | M. Raźny | N. Grzasko | M. Pelosini | M. Dutka | E. Subocz | A. Druzd-Sitek | M. Rymko | M. Wątek | A. Macauda | E. Iskierka-Jażdżewska | A. Belachew | M. Dudzinski | Alyssa I. Clay-Gilmour | Eva Kannik Haastrup | Chiara Piredda | Lene Hyldahl Ebbesen | E. Brown | Alem A Belachew
[1] H. Brenner,et al. Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study , 2019, Leukemia & lymphoma.
[2] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[3] D. Campa,et al. Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients , 2018, British journal of haematology.
[4] Junke Wang,et al. gwasurvivr: an R package for genome wide survival analysis , 2018, bioRxiv.
[5] Henrik Gréen,et al. Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial , 2017, Cancer Chemotherapy and Pharmacology.
[6] B. Weir,et al. A genome-wide study of Hardy–Weinberg equilibrium with next generation sequence data , 2017, Human Genetics.
[7] O. Stephens,et al. A common genetic variant in 19q13·3 is associated with outcome of multiple myeloma patients treated with Total Therapy 2 and 3 , 2016, British journal of haematology.
[8] H. Goldschmidt,et al. A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMEnSE consortium and meta-analysis , 2016, Oncotarget.
[9] Shane A. McCarthy,et al. Reference-based phasing using the Haplotype Reference Consortium panel , 2016, Nature Genetics.
[10] A. Vangsted,et al. Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translation , 2016, International journal of laboratory hematology.
[11] Kenneth G. C. Smith,et al. Insight into Genotype-Phenotype Associations through eQTL Mapping in Multiple Cell Types in Health and Immune-Mediated Disease , 2016, PLoS Genetics.
[12] Manolis Kellis,et al. HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease , 2015, Nucleic Acids Res..
[13] D. Hose,et al. Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells , 2015, BMC Medical Genomics.
[14] G. Castellani,et al. The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) , 2015, Oncotarget.
[15] Nam-Kyung Yu,et al. CTCF as a multifunctional protein in genome regulation and gene expression , 2015, Experimental & Molecular Medicine.
[16] S. Ševčíková,et al. Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data. , 2015, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.
[17] Caleb K. Stein,et al. The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma , 2015, Leukemia.
[18] Lude Franke,et al. From genome to function by studying eQTLs. , 2014, Biochimica et biophysica acta.
[19] J. Crowley,et al. Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma , 2013, Leukemia.
[20] Marcos González,et al. Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma , 2013, British journal of haematology.
[21] G. Requirand,et al. Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors , 2013, British Journal of Cancer.
[22] Ellen T. Gelfand,et al. The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.
[23] Y. Yasukochi,et al. Current perspectives on the intensity of natural selection of MHC loci , 2013, Immunogenetics.
[24] A. McKenna,et al. Integrative eQTL-Based Analyses Reveal the Biology of Breast Cancer Risk Loci , 2013, Cell.
[25] Gareth J. Morgan,et al. A gene expression signature for high-risk multiple myeloma , 2012, Leukemia.
[26] Eurie L. Hong,et al. Annotation of functional variation in personal genomes using RegulomeDB , 2012, Genome research.
[27] F. Vannberg,et al. GENETICS OF GENE EXPRESSION IN PRIMARY IMMUNE CELLS IDENTIFIES CELL-SPECIFIC MASTER REGULATORS AND ROLES OF HLA ALLELES , 2012, Nature Genetics.
[28] U. Vogel,et al. Genetic variations in multiple myeloma II: association with effect of treatment , 2012, European journal of haematology.
[29] V. Moreno,et al. Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review). , 2011, International journal of oncology.
[30] B. Barlogie,et al. The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma , 2011, International journal of hematology.
[31] N. Cox,et al. Trait-Associated SNPs Are More Likely to Be eQTLs: Annotation to Enhance Discovery from GWAS , 2010, PLoS genetics.
[32] Laurence Lodé,et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] L. Liang,et al. A genome-wide association study of global gene expression , 2007, Nature Genetics.
[34] Yongsheng Huang,et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.
[35] Shaji K. Kumar,et al. Multiple Myeloma: Diagnosis and Treatment. , 2005, Mayo Clinic proceedings.
[36] M. Urashima,et al. Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells. , 1996, Blood.
[37] Toshio Matsumoto,et al. TGF-β-related mechanisms of bone destruction in multiple myeloma. , 2011, Bone.
[38] H. Goldschmidt,et al. Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma , 2022 .
[39] Jennifer L. Caswell-Jin,et al. Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients , 2022 .